Skip to content
Advertisement

An Israeli flag flies outside a Teva Pharmaceutical Industries building on Dec. 14, 2017, in Neot Hovav, Israel. The generic drug maker Teva Pharmaceuticals agreed Monday, Aug. 21, 2023, to pay $225 million to settle price-fixing charges related to sales of a major cholesterol-lowering drug. The U.S. Department of Justice said the agreement also requires Teva to divest its business making and selling the drug, pravastatin, a generic version of the brand-name medicine Pravachol. (AP Photo/Tsafrir Abayov, File)

An Israeli flag flies outside a Teva Pharmaceutical Industries building on Dec. 14, 2017, in Neot Hovav, Israel. The generic drug maker Teva Pharmaceuticals agreed Monday, Aug. 21, 2023, to pay $225 million to settle price-fixing charges related to sales of a major cholesterol-lowering drug. The U.S. Department of Justice said the agreement also requires Teva to divest its business making and selling the drug, pravastatin, a generic version of the brand-name medicine Pravachol. (AP Photo/Tsafrir Abayov, File)

Featured Photo Galleries